Loading
A phase 2/3 trial in lung cancer, run by Second Affiliated Hospital of Guangzhou Medical University, now recruiting.
Interventional Software for Multi-immunotherapy of Solid Tumors is a phase 2/3, interventional study registered as NCT06478108 by Second Affiliated Hospital of Guangzhou Medical University, with a registry enrolment figure of 60 participants, started 2024-04-01 and due to reach its primary completion in 2028-12-30. Interventions recorded: IRSW-MIM. Conditions listed: Lung Cancer; Liver Cancer; Solid Tumor, Adult. Primary outcome: Safety of the reccommended treatment generated by the medical device; Progression-free survival; Disease control rate. Sites: China. No results are recorded here; the registry entry is the source.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.